Table 3.

Odds ratio and 95% confidence intervals of cholangiocarcinoma associated with cumulative DDD dose of statin uses

	Case numbers/control numbers	Odds ratio	(95% CI)
Non-use of statins	2454/2334	1.00	(reference)
All statins*
<50 DDD	210/227	0.86	(0.70, 1.05)
50 − 149 DDD	157/187	0.79	(0.64, 0.99)*
≥ 150 DDD	353/426	0.78	(0.66, 0.91)**
P for trend		<0.001
Simvastatin†
<80 DDD	131/163	0.76	(0.58, 0.99)*
≥80 DDD	118/148	0.74	(0.56, 0.98)*
Lovastatin†
<80 DDD	136/160	0.74	(0.57, 0.96)*
≥80 DDD	107/162	0.55	(0.41, 0.73)***
Pravastatin†
<55 DDD	62/77	0.72	(0.48, 1.08)
≥55 DDD	64/90	0.64	(0.44, 0.94)*
Fluvastatin†
<300 DDD	64/89	0.68	(0.47, 0.99)*
≥300 DDD	73/71	1.22	(0.81, 1.84)
Atorvastatin†
<65 DDD	165/196	0.84	(0.66, 1.08)
≥65 DDD	164/199	0.78	(0.62, 0.98)*
Rosuvastatin†
<35 DDD	68/63	1.01	(0.66, 1.56)
≥35 DDD	57/74	0.75	(0.50, 1.12)

^*The cumulative DDD dose is partitioned into three segments for the first quartile, second quartile and third and fourth quartiles combined.

^†The cumulative DDD dose is partitioned into two segments by median.

^*P < 0.05,

^**P < 0.01